Antigen associated with lung cancers and lymphomas
AssigneePhilogen S.P.A.
InventorsDario Neri, Alessandra Villa, Eveline Trachsel, Jascha-Nikolai Rybak
Life of this patent
Estimating the term…
Abstract
The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of lung cancer and lymphoma.
Claims25
A method of treating lung cancer or lymphoma in an individual, comprising administering to the individual a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, which binds Extra Domain-A (ED-A) of fibronectin comprising a VH domain and a VL domain:
- wherein the VH domain comprises a framework and a set of complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein:
- HCDR1 has amino acid sequence SEQ ID NO:
- 83;
- HCDR2 has amino acid sequence SEQ ID NO:
- 4;
- and
- HCDR3 has amino acid sequence SEQ ID NO:
- 5;
- and
- wherein the VL domain comprises a framework and a set of complementarity
- determining regions LCDR1, LCDR2 and LCDR3, wherein:
- LCDR1 has amino acid sequence SEQ ID NO:
- 86;
- LCDR2 has amino acid sequence SEQ ID NO:
- 7;
- and
- LCDR3 has amino acid sequence SEQ ID NO:
- 8;
- and
- wherein the antibody is conjugated to a molecule that has biocidal or cytotoxic activity or is conjugated to a radioisotope.
A method of delivering a molecule to neovasculature of a lung tumour or a lymphoma in a human or animal, wherein the lung tumour is a tumour in the lung which is the result of lung cancer, and wherein the method comprises administering to the human or animal an antibody, or antigen-binding fragment thereof, which binds Extra Domain-A (ED-A) of fibronectin comprising a VH domain and a VL domain:
- wherein the VH domain comprises a framework and a set of complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein
- HCDR1 has amino acid sequence SEQ ID NO:
- 83;
- HCDR2 has amino acid sequence SEQ ID NO:
- 4;
- and
- HCDR3 has amino acid sequence SEQ ID NO:
- 5;
- and
- wherein the VL domain comprising a framework and a set of complementarity
- determining regions LCDR1, LCDR2 and LCDR3, wherein:
- LCDR1 has amino acid sequence SEQ ID NO:
- 86;
- LCDR2 has amino acid sequence SEQ ID NO:
- 7;
- and
- LCDR3 has amino acid sequence SEQ ID NO:
- 8;
- and
- wherein the antibody is conjugated to the molecule.
A method of targeting the neovasculature of a lung tumour or a lymphoma in a human or animal, wherein the lung tumour is a tumour in the lung which is the result of lung cancer, and wherein the method comprises administering to the human or animal an antibody, or antigen-binding fragment thereof, which binds Extra Domain-A (ED-A) of fibronectin comprising:
- a VH domain and a VL domain, wherein the VH domain comprises a framework and a set of complementarity determining regions HCDR1,
- HCDR2 and HCDR3, wherein
- HCDR1 has amino acid sequence SEQ ID NO:
- 83;
- HCDR2 has amino acid sequence SEQ ID NO:
- 4;
- and
- HCDR3 has amino acid sequence SEQ ID NO:
- 5;
- and
- wherein the VL domain comprising a framework and a set of complementarity
- determining regions LCDR1, LCDR2 and LCDR3, wherein:
- LCDR1 has amino acid sequence SEQ ID N086;
- LCDR2 has amino acid sequence SEQ ID NO:
- 7;
- and
- LCDR3 has amino acid sequence SEQ ID NO:
- 8;
- and
- wherein the antibody is conjugated to a molecule that has biocidal or cytotoxic activity or is conjugated to a radioisotope.
Dependencies are inferred from the claim text.